Seagen/ US81181C1045 /
2023-12-13 9:59:59 PM | Chg. - | Volume | Bid1:50:00 AM | Ask1:50:00 AM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
228.7400USD | - | 20.08 mill. Turnover: 1.91 bill. |
228.9100Bid Size: - | 228.9600Ask Size: - | 43.15 bill.USD | - | - |
GlobeNewswire
04-30
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervica...
GlobeNewswire
04-23
Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immu...
GlobeNewswire
03-20
LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results
GlobeNewswire
03-05
LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd...
GlobeNewswire
03-04
Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of ...
GlobeNewswire
02-15
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corp...
GlobeNewswire
01-25
LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1...
GlobeNewswire
01-08
Nurix Therapeutics Outlines 2024 Strategic Priorities with Advancement of Targeted Protein Modulatio...
GlobeNewswire
2023-12-19
Related Sciences Adds 8 New Senior Advisors Including Former CEOs and Heads of R&D from Genentech, N...
GlobeNewswire
2023-11-16
Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
GlobeNewswire
2023-11-07
Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate Updates
GlobeNewswire
2023-11-07
Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update